This page is a soft redirect. Names
This page is a soft redirect. Identifiers#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-
This page is a soft redirect. Properties
This page is a soft redirect. Pharmacology
Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A). Phase II clinical trials in adult patients with refractory partial seizures were promising. Positive preliminary results from stage III trials have been recorded, along with evidence that it is around 10 times more potent for the prevention of certain types of seizure in mouse models than levetiracetam, of which it is an analogue.
- von Rosenstiel P (Jan 2007). "Brivaracetam (UCB 34714)". Neurotherapeutics 4 (1): 84–7. PMID 17199019. doi:10.1016/j.nurt.2006.11.004.
- Malawska B, Kulig K (Jul 2005). "Brivaracetam UCB". Current Opinion in Investigational Drugs 6 (7): 740–746. PMID 16044671.
- Rogawski MA, Bazil CW (Jul 2008). "New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels". Current Neurology and Neuroscience Reports 8 (4): 345–352. PMC 2587091. PMID 18590620. doi:10.1007/s11910-008-0053-7.
- Clinical trial number NCT00464269 for "Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures" at ClinicalTrials.gov
- Rogawski MA (Aug 2008). "Brivaracetam: a rational drug discovery success story". British Journal of Pharmacology 154 (8): 1555–7. PMC 2518467. PMID 18552880. doi:10.1038/bjp.2008.221.
- Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H (Aug 2008). "Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A". British Journal of Pharmacology 154 (8): 1662. PMID 18500360. doi:10.1038/bjp.2008.198.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.